Make an Appointment


Category: Blogs

September 25, 2016

drRegenerative adjunctive treatment is the next logical step in the progression of surgical intervention. The new

paradigm shift in stem cell research has been reflected in the field of or thopaedic indications with limited therapeutic approach which could be benefited using cellular therapy. The relative lack of blood supply as compared with other tissues make these structures incapable of quick healing like other body organs. Consequently, chronicity tends to become a hallmark of musculoskeletal injuries. Clinical use of stem cells have been used in cases of non-unions, avas- cular necrosis (AVN), spinal fusions, bone defects, tendon healing and cartilage repair etc.

Bone is an excellent tissue and the natural tendency of bone when fractured is to unite by forming bone. Non-union results from a gap at the fracture site resulting from bone loss. Non/delayed unions occur in approximately 5-20% of fractures and despite their regular occurrence, management remains challenging. They are defined as non-bridged areas after 6 months of periosteal and endosteal healing and results in severe functional impairment. The most common

Posted in Blog, Blogs by novacord
September 25, 2016

A spinal cord injury (SCI) is any injury of the spinal cord caused due to trauma and mostly comprise of damage to the nerves associated with the spinal cord and they can be classified as being complete or incomplete. Spinal cord injuries account for a majority of lower body disabilities due to accidents and trauma. Cell transplantation, as a therapeutic intervention for spinal cord injury (SCI), has been extensively studied by scientists and researchers in recent years using stem cell that has shown considerable promise in treating patients with SCI and thus restores lost functions by replacing lost or damaged cell populations. Spinal cord injuries account for a majority of lower body disabilities due to accidents and trauma. SCI also paves way for a lot of other disabilities associated with blood vessels as well and bone deformities. The global burden of SCI, economically, runs into millions as complete cure is not possible. The number of clinical trials that have been conducted for phase 1 studies of spinal cord injury is a staggering number and currently 246 trials are being conducted in their initial phases. However, many questions remain unanswered and more continue to emerge. This review will comprehensively cover publications in the field from the last years and examine the biological effects of SCI.